Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/Progesterone Receptor Status in the Shanghai Breast Cancer Study
Authors:
- Xiao Ou ShuXSXiao Ou Shu
- Yu-Tang GaoYGYu-Tang Gao
- Ying ZhengYZYing Zheng
- Hui CaiHui Cai
- Sandra L. DemingSDSandra L. Deming
- Zhi-Xian RuanZRZhi-Xian Ruan
- Yinghao SuYSYinghao Su
- Kai GuKGKai Gu
- Wei LuWLWei Lu
- Wei ZhengWZWei Zheng
Open Access
- 18 July 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 174 (6) , 661-671
Abstract
Etiologic differences between subtypes of breast cancer defined by estrogen receptor (ER) and progesterone receptor (PR) status are not well understood. The authors evaluated associations of hormone-related factors with breast cancer subtypes in a population-based case-control study involving 1,409 ER-positive (ER+)/PR-positive (PR+) cases, 712 ER-negative (ER−)/PR-negative (PR−) cases, 301 ER+/PR− cases, 254 ER−/PR+ cases, and 3,474 controls aged 20–70 years in Shanghai, China (phase I, 1996–1998; phase II, 2002–2005). Polytomous logistic regression and Wald tests for heterogeneity across subtypes were conducted. Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first livebirth, waist-to-hip ratio, and oral contraceptive use did not differ by hormone receptor status. Among postmenopausal women, higher parity (≥2 children vs. 1) was associated with reduced risk (odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.52, 0.91) and higher body mass index (BMI; weight (kg)/height (m)2) with increased risk (highest quartile: OR = 2.40, 95% CI: 1.65, 3.47) of the ER+/PR+ subtype but was unrelated to the ER−/PR− subtype (for parity, Pheterogeneity = 0.02; for BMI, Pheterogeneity < 0.01). Hormone replacement therapy (OR = 2.25, 95% CI: 1.40, 3.62) and alcohol consumption (OR = 1.59, 95% CI: 1.01, 2.51) appeared to be preferentially associated with the ER+/PR− subtype. These findings indicate that BMI, parity, hormone replacement therapy, and alcohol consumption may play different roles in subtypes of breast cancer. More research is needed to better understand the etiology of 2 relatively rare subtypes, ER+/PR− tumors and ER−/PR+ tumors.Keywords
This publication has 38 references indexed in Scilit:
- Soy product and isoflavone intake and breast cancer risk defined by hormone receptor statusCancer Science, 2010
- Menopausal Hormone Therapy and Risk of Clinical Breast Cancer SubtypesCancer Epidemiology, Biomarkers & Prevention, 2009
- Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort StudyAmerican Journal of Epidemiology, 2009
- Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study CohortCancer Epidemiology, Biomarkers & Prevention, 2008
- Breast Cancer Risk and Hormone Receptor Status in Older Women by Parity, Age of First Birth, and Breastfeeding: A Case-Control StudyCancer Epidemiology, Biomarkers & Prevention, 2008
- Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor–Defined Invasive Breast CancerJournal of Clinical Oncology, 2008
- Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancerNature Clinical Practice Oncology, 2007
- Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal WomenCancer Epidemiology, Biomarkers & Prevention, 2006
- Association of Physical Activity with Hormone Receptor Status: The Shanghai Breast Cancer StudyCancer Epidemiology, Biomarkers & Prevention, 2006
- Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinomaCancer, 2004